Lataa...
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease
Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multi-k...
Tallennettuna:
| Julkaisussa: | Biol Blood Marrow Transplant |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4425991/ https://ncbi.nlm.nih.gov/pubmed/25771402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.03.006 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|